Hepatitis C 新藥 solvadi
發表於 : 週三 4月 09, 2014 3:02 pm
美國以發表C肝癌最新用藥 Solvadi sofosbuvir.
研究效果良好,但是一療程美金$8萬。
全民健保 應無法負擔。 自費市場應該相當可觀
http://hepatitiscnewdrugs.blogspot.tw/2 ... 0.html?m=1
Solvadi (sofosbuvir) - Holy Inhibitors Santa And December Hepatitis C Newsletters
December Hepatitis C Newsletters
**Updated Dec 19 - Check out The American Liver Foundation newsletter; Liver Low Down and this months Hepatitis C News "Video Broadcast" - provided below.
Hello folks, welcome to this months edition of newsletters, brought to you by a small group of exceptional people devoted to bringing awareness, support and information to the HCV community.
As you all know by now, in the last few weeks two new oral drugs were approved by the U.S. Food and Drug Administration to treat hepatitis C, Merry Christmas to us!
The first drug was approved in November, Olysio (simeprevir) a protease inhibitor for people with HCV genotype 1 used in combination with interferon and ribavirin. The second drug is Solvadi (sofosbuvir) the first FDA approved polymerase inhibitor, used for genotypes 1 and 4, in combination with interferon and ribavirin. As for people with genotypes 2 and 3 Solvadi is used with ribavirin alone, making it the first interferon free combination!
We start out with a video from Joe Galati, M.D., covering some HCV basics, followed by information on future and current direct-acting antivirals including a quick summary of Gilead's clinical trial data and finally background information on this months HCV newsletters.
研究效果良好,但是一療程美金$8萬。
全民健保 應無法負擔。 自費市場應該相當可觀
http://hepatitiscnewdrugs.blogspot.tw/2 ... 0.html?m=1
Solvadi (sofosbuvir) - Holy Inhibitors Santa And December Hepatitis C Newsletters
December Hepatitis C Newsletters
**Updated Dec 19 - Check out The American Liver Foundation newsletter; Liver Low Down and this months Hepatitis C News "Video Broadcast" - provided below.
Hello folks, welcome to this months edition of newsletters, brought to you by a small group of exceptional people devoted to bringing awareness, support and information to the HCV community.
As you all know by now, in the last few weeks two new oral drugs were approved by the U.S. Food and Drug Administration to treat hepatitis C, Merry Christmas to us!
The first drug was approved in November, Olysio (simeprevir) a protease inhibitor for people with HCV genotype 1 used in combination with interferon and ribavirin. The second drug is Solvadi (sofosbuvir) the first FDA approved polymerase inhibitor, used for genotypes 1 and 4, in combination with interferon and ribavirin. As for people with genotypes 2 and 3 Solvadi is used with ribavirin alone, making it the first interferon free combination!
We start out with a video from Joe Galati, M.D., covering some HCV basics, followed by information on future and current direct-acting antivirals including a quick summary of Gilead's clinical trial data and finally background information on this months HCV newsletters.